Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Short Candidates -- Ignore unavailable to you. Want to Upgrade?

To: Spekulatius who wrote (423)	2/28/2003 9:21:36 AM
From: Biomaven	Read Replies (1) \| Respond to of 897

Cowen has just come out with a report saying that MEDI fundamentals are some of the best in biotech and MEDI should be a core holding. MEDI/Wyeth have gone for a premium pricing strategy for FluMist, and Cowen suggests that a prospective vaccine shortage for the next season suggests they will have no trouble selling their initial 4-6m doses. Cowen is forecasting substantial earnings growth over the next 5 years. The '02 thru '06 period is projected to have a 46% CAGR in cash (i.e., excluding non-cash items) earnings. My own view is that FluMist will indeed be a blockbuster and sales of $1 billion (of which MEDI gets half) are not out of reach within 5 years. (Assuming no nasty surprises, of course). Peter